The bronchiectasis market encompasses pharmaceuticals, where companies develop medications such asantibiotics, mucolytics, and bronchodilators to manage symptoms and improve patients' quality of life. There's a growing interest in novel therapies, such as anti-inflammatory agents and mucolytic enzymes, aimed at addressing underlying causes and reducing disease progression. Alongside pharmaceuticals, the market includes diagnostic tools and devices crucial for early detection and monitoring of bronchiectasis. Overall, this market strives to offer comprehensive solutions to address the diverse challenges of chronic respiratory conditions, from symptom management to disease modification.
The Global Bronchiectasis Market valued at USD 562.92 million in 2023 is projected to reach 959.15 million by 2031 and will grow at a CAGR of 6.10% during the forecast period of 2024-2031.
Below are the Top Bronchiectasis Companies with a Significant Market Share:
|
Rank
|
Company
|
Overview
|
Product Portfolio
|
Sales Geographical Coverage
|
Developments
|
|
1.
|
AstraZeneca
|
A multinational pharmaceutical company, AstraZeneca develops and markets a range of respiratory medications, including treatments for bronchiectasis. With a focus on innovation, they strive to provide effective therapies to manage symptoms and improve outcomes for bronchiectasis patients.
|
|
Europe, Americas, Middle East and Africa, Asia-Pacific
|
In June 2019, AstraZeneca received approval for Breztri Aerosphere (PT010) in Japan for the treatment of COPD. Breztri Aerosphere comprises budesonide/glycopyrronium/ formoterol fumarate and proved to be a new treatment choice among people suffering from lung inflammation and other chronic obstructive diseases. This approval helped the company to earn constant sales by expanding its product sales across several regions of the world.
|
|
2.
|
GSK plc.
|
GSK is a leading global healthcare company known for its expertise in respiratory medicine. They offer a portfolio of bronchiectasis medications, including antibiotics and inhalers, aiming to address the diverse needs of patients while continuously investing in research and development to advance treatment options.
|
|
Europe, Middle East and Africa, South America, North America, Australia, Central America and Asia-Pacific
|
In September 2020, GlaxoSmithKline plc. received approval for Trelegy Ellipta from the U.S FDA for the treatment of asthma and other COPD diseases in the U.S. This approval paved the way for product approval. It allowed the company to expand its portfolio of innovative medicines for patients suffering from respiratory diseases.
|
|
3.
|
Teva Pharmaceuticals USA, Inc.
|
Teva Pharmaceuticals is a prominent player in the pharmaceutical industry, with a commitment to providing affordable and accessible healthcare solutions. They offer medications for bronchiectasis management, contributing to the availability of essential therapies for patients worldwide.
|
|
North America
|
In October 2020, Teva Pharmaceutical USA Inc. (A Subsidiary of Teva Pharmaceutical Industries Ltd.) went under collaboration with Amazon Web Services and Onica to support the Digihaler product portfolio. This collaboration helped the company to leverage the best- in class breed capabilities of digital respiratory health technologies. This initiative helped the company advance existing technologies to achieve constant growth in the market.
|
|
4.
|
Merck & Co., Inc.
|
Merck is a renowned pharmaceutical company with a strong focus on respiratory health. They develop and market medications for bronchiectasis, leveraging their expertise in drug discovery and development to address the complex challenges associated with the condition.
|
|
Europe, Middle East and Africa, South America, North America, and Asia-Pacific
|
In June 2020, Merck Sharp & Dohme Corp. (A subsidiary of Merck & Co., Inc.) acquired Themis, a company focused on manufacturing advanced immune modulating therapies targeting infectious disease, among others. This acquisition accelerated the company’s research and developmental activities and allowed it to attain lucrative growth in the market.
|
|
5.
|
Medline Industries, Inc.
|
Medline is a leading manufacturer and distributor of medical supplies and equipment, including products used in the diagnosis and management of bronchiectasis. Their range of respiratory care solutions supports healthcare professionals in delivering effective treatment and improving patient outcomes in the bronchiectasis market.
|
|
Europe, Middle East and Africa, South America, North America, and Asia-Pacific
|
In March 2019, Novartis AG launched COPD inhalers in China. The company has launched Ultibro Breezhaler and Seebri Breezhaler inhalers, which have been proven efficacious for the treatment of infectious and inflammatory respiratory problems. This initiative boosted the company’s product portfolio and helped it to expand its roots in the bronchiectasis market.
|
Conclusion
In the bronchiectasis market, companies such asAstraZeneca, GSK plc, Teva Pharmaceuticals USA, Inc., Merck & Co., Inc., and Medline Industries, Inc. play vital roles in providing comprehensive solutions for patients. Through their innovative pharmaceuticals, diagnostic tools, and respiratory care products, they contribute to managing symptoms, improving patient outcomes, and advancing the understanding of bronchiectasis. With a commitment to research, development, and accessibility, these companies collectively strive to address the diverse needs of individuals affected by this chronic respiratory condition, underscoring their dedication to respiratory health and enhancing the quality of life for bronchiectasis patients worldwide.
